Li Sheng Zhao Spends CN¥436k On Kingworld Medicines Group Stock
Li Sheng Zhao Spends CN¥436k On Kingworld Medicines Group Stock
Even if it's not a huge purchase, we think it was good to see that Li Sheng Zhao, the Co-Founder of Kingworld Medicines Group Limited (HKG:1110) recently shelled out HK$436k to buy stock, at HK$0.44 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.
即使這不是一筆巨額交易,我們認爲金活醫藥集團有限公司(HKG:1110)的聯合創始人李勝趙最近以每股0.44港元的價格斥資43.6萬港元購買股票是件好事。然而,這僅僅增加了他們的股東持股比例很小,絕對價值也不算巨大。
Kingworld Medicines Group Insider Transactions Over The Last Year
金活醫藥集團一年內的內部交易情況
Notably, that recent purchase by Li Sheng Zhao is the biggest insider purchase of Kingworld Medicines Group shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of HK$0.41. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Li Sheng Zhao.
值得注意的是,李勝趙最近的這次購買是金活醫藥集團股份在過去一年內最大的內部人士購買。這意味着內部人士願意以上市價0.41港元以上的價格購買股票。他們很可能對此次交易感到後悔,但更可能是看好這家公司。對我們來說,考慮內部人士購買股票的價格非常重要。一般來說,當內部人士以高於當前股價購買股票時,我們會關注,因爲這表明他們認爲這些股票值得購買,即使價格較高。過去一年中唯一一位個人內部人士的購買者是李勝趙。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以在下面的圖表中查看過去一年(由公司和個人)的內部交易。通過單擊下面的圖表,您可以查看每個內部交易的詳細信息!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
還有很多其他的公司,公司的內部人士正在購買股票。你可能不想錯過這個免費的小市值公司的低估列表。
Does Kingworld Medicines Group Boast High Insider Ownership?
金活醫藥集團是否擁有高內部股權所有權?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kingworld Medicines Group insiders own about HK$168m worth of shares (which is 70% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
對於普通股東而言,值得檢查公司內部人員持有多少股份。我認爲,如果內部人員擁有公司內一定數量的股份,這是一個好跡象。金活醫藥集團的內部人員擁有價值約爲HK$16800萬的股份(約佔公司股份的70%)。我喜歡看到這種內部股權所有權水平,因爲這增加了管理層考慮股東最佳利益的機會。
So What Does This Data Suggest About Kingworld Medicines Group Insiders?
那麼這些數據對金活醫藥集團的內部人員意味着什麼?
It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Kingworld Medicines Group. Nice! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Kingworld Medicines Group has 2 warning signs we think you should be aware of.
最近的內部人員購買情況確實令人振奮。對過去一年交易的分析也增強了我們的信心。一旦考慮到高內部人員持股,看起來內部人員對金活醫藥集團持樂觀態度。不錯!因此,了解內部人員在購買或出售方面的行爲是很有幫助的,同時了解某家公司面臨的風險也很有幫助。舉例來說——金活醫藥集團有2個警示跡象,我們認爲您應該意識到。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。